Drug Discovery

Lonza

Watch our expert, Maureen Bunger, PhD, explain how our patented manufacturing process ensures that the DonorPlex™ Hepatocytes exhibit improved phenotype reproducibility. Additionally, we have a proprietary algorithm that predicts yield, viability and functional phenotype prior to manufacture which ensures individual customer specifications are met.

Learn more about DonorPlex™ Pooled Donor Human Hepatocytes:
https://bioscience.lonza.com/pooled-human-donor-hepatocytes

Learn how Lonza can support your liver research applications:
https://bioscience.lonza.com/liver-studies-for-adme-tox-studies

DonorPlex™ Pooled Donor Human Hepatocytes products from Lonza:
https://bioscience.lonza.com/search/?text=donorplex


#ADME #Toxicology #Drugmetabolism #pharmacokinetic #DrugDiscovery #hepatocytes #primarycells #FDA #Lonza #DrugDrugInteraction #DDI

DonorPlex™ Pooled Donor Human Hepatocytes Enable the Next Level of Reliability | Lonza

Advance your in vitro drug interaction studies to the next level! Watch this video to learn how our Interaction Qualified primary hepatocytes can increase your confidence in your DDI and metabolism studies.

Learn more about Interaction Qualified Primary Hepatocytes: https://bioscience.lonza.com/lonza_bs/US/en/interaction-qualified-hepatocytes


Learn how Lonza can support your liver research applications: https://bioscience.lonza.com/liver-studies-for-adme-tox-studies

Cryopreserved primary hepatocytes products from Lonza: https://bioscience.lonza.com/Catalogue/Products/ADME-and-Toxicology/c/5?q=%3A%3A%3A%3Alonza-sort%3A%3A%3A%3Alon_cl_PrimaryCellType%3A%3A%3A%3AHepatocytes
#ADME #Toxicology #Drugmetabolism #pharmacokinetic #DrugDiscovery #hepatocytes #primarycells #FDA #Lonza #DrugDrugInteraction #DDI

Interaction Qualified Primary Hepatocytes | Lonza Product Overview

BÜCHI Labortechnik AG

Gain valuable information on spray drying theory and applications. Two experts in the field cover topics such as:

- Comprehensive overview of the spray drying and encapsulation process
- Your spray dryer: how it works, how to use it, how to maintain it
- Tips for improving your spray drying parameters
- Spray drying for different applications

How to optimize your spray drying process

Sekisui XenoTech

Presenter: Pallavi Limaye, Ph.D., DABT, SEKISUI XenoTech Director of Scientific Consulting

Abstract:
Aldehyde oxidase (AO) enzyme has gained increasing attention in drug development as one of the alternative approaches to reduce P450-mediated drug metabolism liability. However, clinical failure due to poor prediction of AO-mediated clearance is a major hurdle in development of drugs that are AO substrates. In vitro to in vivo extrapolation underpredicts AO-mediated drug clearance owing to several factors including lack of reliable representative animal models, marked species differences, significant inter-individual variability, substrate-specific activity, and discrepancy between absolute concentration and activity. To tackle these issues related to underprediction of AO-mediated drug clearance, in vitro tools to extrapolate in vivo clearance involving a yardstick approach are proposed. AO-metabolism is an attractive strategy to reduce P450-mediated drug metabolism liability but careful consideration of the unique challenges is essential.

Key concepts discussed in this webinar will include:
 - Wide range of AO substrates – Functional groups
 - AO substrate drugs that faced clinical failure unanticipated drug clearance
 - Underprediction and Factors affecting AO expression
   - Age, Disease state, Alcohol consumption, Pharmacogenomics
   - Species differences
   - Inter-individual variability
   - Sample handling, Freeze-thaw cycles, Fresh vs. Frozen tissue
 - In vitro AO inhibition and fm AO determination
 - In vitro yardstick approach

Request a copy of the slides: https://www.xenotech.com/about/events/webinar-underprediction-of-drug-clearance-by-aldehyde-oxidase-ao-mediated-drug-metabolism-important-considerations-for-in-vitro-assessment/
Questions, comments and requests: https://www.xenotech.com/contact/
More information on our research services and test systems: https://www.xenotech.com
Other previously aired webinars: https://www.xenotech.com/access-adme-research-resources/resource-type/webinar/
Upcoming webinar notifications: https://www.xenotech.com/contact/newsletter-sign-up/
Request a webinar topic: https://www.xenotech.com/contact/webinar-seminar-request/

About the Presenter:
Pallavi Limaye is a Director in the Scientific Consulting department. Pallavi received her Ph.D. in Toxicology from The University of Louisiana. Dr. Limaye originally joined SEKISUI XenoTech in 2011 as a Research Scientist and served as a study director for in vitro drug metabolism studies. In 2020, she joined SEKISUI XenoTech’s consulting team and provides input on drug-drug interaction study needs for sponsors. Dr. Limaye has published several original research articles in various journals and has also contributed many book chapters in the field of toxicology and liver pathobiology. She is also actively involved in scientific societies and currently serves on the E-Learning Subcommittee of The American College of Toxicology and is the current President of the Central States regional chapter of The Society of Toxicology.

Underprediction of Drug Clearance by Aldehyde Oxidase (AO)–Mediated Drug Metabolism (Webinar)

INTEGRA Biosciences

The MINI 96 is the solution for laboratories that want to fill 96 and 384 well plates faster and more precisely than is possible using traditional handheld pipettes while keeping under budget. As the world’s most affordable 96 channel option on the market, it enables simultaneous whole plate pipetting – as well as partial plate filling – to ensure that your lab’s productivity skyrockets compared to 8 and 12 channel pipettes. 

Learn more: 
https://www.integra-biosciences.com/united-kingdom/en/electronic-pipettes/mini-96

MINI 96 – 96 Channel Portable Electronic Pipette

Biotech Videos 

Future cancer and other infectious disease treatments require a new type of cargo that precisely delivers the medicine to its specific target without causing undesired side-effects on healthy cells and tissue. This concept is fully demonstrated by antibody-drug conjugates, or ADCs, which combines the accurate targeting feature of a monoclonal antibody with highly cytotoxic payloads to achieve the strike of the lesion site as a precision-guided munition.
https://www.creative-biolabs.com/adc/

What is ADC

Three major components define an ADC—the monoclonal antibody, a cytotoxic payload, and a molecular linker that covalently bridges the other two components. A successful ADC should be chemically and physiologically stable in blood stream, exert similar antigen binding pattern compared with the unconjugated antibody, and exhibit desired payload toxicological effects once internalized.https://www.creative-biolabs.com/adc/adc-manufacturing.htm

Basic Knowledge of ADC

Monoclonal antibody-based immunotherapies against cancer and other infectious diseases are highly advantageous comparing to conventional therapeutic approaches due to their high specificity and affinity towards well-defined targets. Antibody-drug conjugates (ADCs) inherit such superiorities and more remarkably, expand the therapeutic window of the conjugated drugs (payloads), which are usually highly toxic and diverse in their biochemical nature.https://www.creative-biolabs.com/adc/one-stop-adc-development-service.htm

A Brief Introduction of Antibody Drug Conjugate

Analytical Cannabis 

Speaking at the Analytical Cannabis Expo East Online 2020 back in October, Rob Dhoble, Managing Director at Havas ECS discussed a dual regulatory framework path to improve the needs of healthcare and selfcare. 

Abstract: Many Americans utilize OTC remedies in an attempt to fill the Rx affordability gap. In fact, 31% of surveyed adults report that they or a family member have relied upon home remedies or over-the-counter drugs instead of going to see a doctor, and 18% report not filling an Rx due to cost and taking an OTC product instead.
With large populations of individuals living with unmet and poorly met chronic medical needs, and the availability of relatively few FDA approved prescription cannabinoids, each narrowly labeled, and the widespread commercial availability of federally unregulated non-Rx cannabis products and non-intoxicating cannabinoids such as cannabigerol (CBG) and cannabidiol (CBD), our healthcare marketplace urgently requires a dual-path approach to ensure affordability, and market access to quality Rx and quality non-Rx cannabinoids for use under direction of medical professionals, and for use as non-Rx cannabinoids comprising ”selfcare”.   Specifically, a new “brief summary” non-Rx cannabinoid requirement is proposed, uniformly depicted on product packaging and within product advertising, to summarize the presence or absence of:
• independent laboratory assessed listing of product ingredients including CBD, THC, and other cannabinoids; linalool, myrcene, and other terpenes, inert ingredients, and the absence of contaminants
• identification of ingredients as being botanical, synthetic, or bio-synthetic 
• cGMP FDA compliance in manufacturing and packaging, including package expiration
• bioavailability data in how dose/serving size relates to absorption and blood levels

Rx and non-Rx Cannabinoids: A dual path regulatory framework for market access and product quality, to better support the needs of healthcare and selfcare.

Drug Discovery

Refine By

Keep up to date with all your favourite videos and channels.

Get personalised notifications on new releases and channel content by subscribing to the LabTube eNewsletter.